Checkmate Pharmaceuticals, Inc.

CMPICIK 0001651431 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 29, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0000

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Checkmate Pharmaceuticals, Inc.

Name	Roles	Filings
Wooldridge James	Officer	3
Bash Alan	OfficerDirector	2
Dolski Robert	Officer	2
Wigginton Jon Marc	Director	2
Colabuono Peter	Director	1

Showing 6-10 of 16

Per pagePrevPage 2 of 4Next

All filings

23 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
May 31, 2022	Bash Alan Chief Executive Officer · Director	Holdings only	-	-	-
May 31, 2022	Fuhrman Alan Director	Holdings only	-	-	-
May 31, 2022	Wigginton Jon Marc Director	Holdings only	-	-	-
May 31, 2022	Wooldridge James Chief Medical Officer	Holdings only	-	-	-
May 31, 2022	Dolski Robert Chief Financial Officer	Holdings only	-	-	-

Showing 1-5 of 23

Per pagePage 1 of 5Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value